ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
04 août 2021 16h15 HE | ARCA biopharma, Inc.
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 ...
Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology
28 juil. 2021 08h00 HE | ARCA biopharma, Inc.
Analysis in full patient cohort shows Gencaro effect compared to standard of careIn the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with...
CentraCare First in World to Use 4D Hologram Technology to Successfully Complete Structural Heart Procedure
23 juin 2021 09h00 HE | EchoPixel
ST. CLOUD, Minn., June 23, 2021 (GLOBE NEWSWIRE) -- CentraCare, one of the largest health systems in Minnesota, has successfully completed the first structural heart procedure in the world using 4D...
InCarda Logo.png
InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation
23 juin 2021 08h05 HE | InCarda Therapeutics, Inc.
Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Data Expected 2H 2022 ...
InCarda Logo.png
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team
09 juin 2021 08h05 HE | InCarda Therapeutics, Inc.
Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in...
Christopher Graybill Joins ARCA as Vice President, Clinical Development
05 mai 2021 16h05 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
TIP_link_300x300.jpg
Anticoagulant Reversal Drugs Market to Garner $2,276.54 Million by 2027 | 12.6% CAGR - Impact of COVID-19 Pandemic and Global Analysis by The Insight Partners
07 avr. 2021 10h00 HE | The Insight Partners
Pune, India, April 07, 2021 (GLOBE NEWSWIRE) -- According to our new research study on “Anticoagulant Reversal Drugs Market to 2027 – Global Analysis and Forecast – by Product and Distribution...
InCarda Logo.png
InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation
19 janv. 2021 08h05 HE | InCarda Therapeutics, Inc.
SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
22157.jpg
Global Atrial Fibrillation Treatment Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast
10 déc. 2020 04h13 HE | Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
InCarda Logo.png
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
13 nov. 2020 10h00 HE | InCarda Therapeutics, Inc.
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of...